Filtered By:
Source: European Journal of Heart Failure
Condition: Heart Failure

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 113 results found since Jan 2013.

Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction
ConclusionsIn patients with both HF‐REF and HF‐PEF, hospitalization for WHF was associated with high early and late mortality. The early relative risk of death was not as great as following MI or stroke, but the longer term relative risk of death was similar following all three types of event. Numerically, more deaths occurred following WHF because it was a much more common event.
Source: European Journal of Heart Failure - December 30, 2014 Category: Cardiology Authors: Søren L. Kristensen, Pardeep S. Jhund, Lars Køber, David Preiss, John Kjekshus, Robert S. McKelvie, Michael R. Zile, Inder S. Anand, John Wikstrand, Hans Wedel, Michel Komajda, Peter E. Carson, John G.F. Cleland, John J.V. McMurray Tags: Original Article Source Type: research

Plasma D ‐dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER‐HF trial
ConclusionsIn COMMANDER-HF, rivaroxaban reduced the risk of stroke but the benefit may be confined to patients with D-dimer concentrations above 515  ng/mL. Prospective trials are warranted to confirm these findings.
Source: European Journal of Heart Failure - June 18, 2021 Category: Cardiology Authors: Jo ão Pedro Ferreira, Carolyn S.P. Lam, Stefan D. Anker, Mandeep R. Mehra, Dirk J. Veldhuisen, William M. Byra, David A. La Police, John G.F. Cleland, Barry Greenberg, Faiez Zannad Tags: Research article Source Type: research

Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease
ConclusionThe placebo‐controlled cohort of heart failure patients with anaemia, diabetes mellitus, and chronic kidney disease from RED‐HF provides confirmation of the increased stroke risk associated with DA use identified in TREAT.
Source: European Journal of Heart Failure - October 1, 2015 Category: Cardiology Authors: Natalie A. Bello, Eldrin F. Lewis, Akshay S. Desai, Inder S. Anand, Henry Krum, John J.V. McMurray, Kurt Olson, Scott D. Solomon, Karl Swedberg, Dirk J. van Veldhuisen, James B. Young, Marc A. Pfeffer Tags: Original Article Source Type: research

Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction
ConclusionThe hemodynamic response to exercise was very heterogenous among patients with HFpEF, with chronotropic incompetence observed in up to 56% and 28% had impaired increase in SVI. This suggests that hemodynamic exercise testing may be useful to identify which HFpEF patients may benefit from interventions targeting stroke volume and chronotropic response.Clinical Trial RegistrationClincaltrial.gov (NCT01913613, NCT02600234, NCT01974557)
Source: European Journal of Heart Failure - March 9, 2021 Category: Cardiology Authors: Emil Wolsk, David M. Kaye, Jan Komtebedde, Sanjiv J. Shah, Barry A. Borlaug, Daniel Burkhoff, Dalane W. Kitzman, John G. Cleland, Gerd Hasenfu ß, Christian Hassager, Jacob E. Møller, Finn Gustafsson Tags: Research Article Source Type: research

Rationale and design of a randomized, double‐blind, event‐driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial
ConclusionCOMMANDER HF is the first prospective study of a target‐specific oral antithrombotic agent in HF. It will provide important information regarding rivaroxaban use following an HF event in an HF‐rEF patient population with coronary artery disease.
Source: European Journal of Heart Failure - April 27, 2015 Category: Cardiology Authors: Faiez Zannad, Barry Greenberg, John G.F. Cleland, Mihai Gheorghiade, Dirk J. van Veldhuisen, Mandeep R. Mehra, William M. Byra, Min Fu, Roger M. Mills Tags: Original Article Source Type: research

Effect of Patisiran on Stroke Volume in Hereditary Transthyretin ‐Mediated Amyloidosis: Insights from Pressure‐Volume Analysis of the APOLLO Study
ConclusionsPatisiran may delay progression of LV chamber dysfunction starting at 9 months of therapy. These data elucidate the mechanisms by which transthyretin reducing therapies modulate progression of cardiac disease and need to be confirmed in ongoing phase III trials.
Source: European Journal of Heart Failure - January 25, 2023 Category: Cardiology Authors: Hannah R. Rosenblum, Jan M. Griffin, Masatoshi Minamisawa, Narayana Prasad, John Vest, Matthew T. White, Scott D. Solomon, M.D. Daniel Burkhoff, Mathew S. Maurer Tags: Research Article Source Type: research

CHA2DS2 ‐VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm
ConclusionsThe CHA2DS2‐VASc score predicted adverse outcomes in patients with systolic heart failure in sinus rhythm, with modest prediction accuracy.
Source: European Journal of Heart Failure - June 30, 2016 Category: Cardiology Authors: Siqin Ye, Min Qian, Bo Zhao, Richard Buchsbaum, Ralph L. Sacco, Bruce Levin, Marco R. Di Tullio, Douglas L. Mann, Patrick M. Pullicino, Ronald S. Freudenberger, John R. Teerlink, J.P. Mohr, Susan Graham, Arthur J. Labovitz, Conrado J. Estol, Dirk J. Lok, Tags: Short Report Source Type: research

Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial
Conclusions The overall benefits of dabigatran for stroke/SE prevention, and major and intracranial bleeding, relative to warfarin in the RE-LY trial were consistent in patients with and without HF.
Source: European Journal of Heart Failure - August 19, 2013 Category: Cardiology Authors: Ferreira, J., Ezekowitz, M. D., Connolly, S. J., Brueckmann, M., Fraessdorf, M., Reilly, P. A., Yusuf, S., Wallentin, L., on behalf of the RE-LY Investigators Tags: TREATMENT Source Type: research

New evidence for favourable effects on haemodynamics and ventricular performance after Parachute® implantation in humans
ConclusionThe data demonstrate the acute haemodynamic efficacy of Parachute device implantation. The implantation of the device displays immediate significant left ventricular volume reduction leading to an acute improved right and left cardiac function, proving the concept of left ventricular partitioning.
Source: European Journal of Heart Failure - October 9, 2014 Category: Cardiology Authors: Tobias Schmidt, Christian Frerker, Thomas Thielsen, Inge Dotz, Peter Wohlmuth, Karl‐Heinz Kuck, Ulrich Schäfer Tags: Original Article Source Type: research

Haemodynamic effects of the nitroxyl donor cimlanod (BMS ‐986231) in chronic heart failure: a randomized trial
ConclusionIn patients with chronic HFrEF, the haemodynamic effects of cimlanod and NTG are similar. The effects of cimlanod may be explained by venodilatation and preload reduction without additional inotropic or lusitropic effects. Ongoing trials of cimlanod will further define its potential role in the treatment of heart failure.
Source: European Journal of Heart Failure - March 9, 2021 Category: Cardiology Authors: Ninian N. Lang, Faheem A. Ahmad, John G. Cleland, Christopher M. O'Connor, John R. Teerlink, Adriaan A. Voors, Jorg Taubel, Anke R. Hodes, Mohamed Anwar, Ravi Karra, Yasushi Sakata, Shiro Ishihara, Roxy Senior, Abhishek Khemka, Narayana G. P Tags: Research Article Source Type: research

Non‐vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta‐analysis of randomized trials
ConclusionAmong AF patients with HF, single‐/high‐dose NOAC regimens have a better efficacy and safety profile, but low‐dose regimens had similar efficacy and safety to warfarin. NOACs were similarly effective or even safer (less intracranial haemorrhage) in AF patients with HF compared with those without HF.
Source: European Journal of Heart Failure - September 3, 2015 Category: Cardiology Authors: Qinmei Xiong, Yee Cheng Lau, Keitaro Senoo, Deirdre A. Lane, Kui Hong, Gregory Y.H. Lip Tags: Original Article Source Type: research

Acceleration of kidney function decline after incident hospitalization with cardiovascular disease: the Stockholm CREAtinine Measurements (SCREAM) Project
ConclusionsIncident hospitalization with cardiac diseases (i.e., HF and CHD) was significantly associated with a subsequent acceleration of eGFR decline.
Source: European Journal of Heart Failure - July 18, 2020 Category: Cardiology Authors: Junichi Ishigami, Marco Trevisan, Lars Lund, Tomas Jernberg, Josef Coresh, Kunihiro Matsushita, Juan ‐Jesus Carrero Pharm Tags: Research Article Source Type: research

Acceleration of kidney function decline after incident hospitalization with cardiovascular disease: the Stockholm CREAtinine Measurements (SCREAM) project
ConclusionsIncident hospitalization with cardiac diseases (i.e. HF and CHD) was significantly associated with a subsequent acceleration of eGFR decline.
Source: European Journal of Heart Failure - August 19, 2020 Category: Cardiology Authors: Junichi Ishigami, Marco Trevisan, Lars H. Lund, Tomas Jernberg, Josef Coresh, Kunihiro Matsushita, Juan ‐Jesus Carrero Tags: Research Article Source Type: research